priavoid.com
  • Home
  • About us
    • Overview
    • Strategy
    • Management
    • Supervisory Board
    • Scientific Advisory Board
    • History
  • Drug Development
    • Therapeutic Focus
    • Technology
    • Pipeline
  • Investors and Media
    • News
    • Events
    • Partnering
    • Archive
  • Contact us
    • Careers
Seite wählen

Clinical trial with PRI-002

Learn More

PRI-002 completed the MAD part of the phase I study up to 320mg/subject/day orally for 28 days to healthy volunteers with very good safety results on 03rd April 2019.

News & Events:

Priavoid closes financing round
Priavoid closes financing round

12. Februar 2021

Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie
Sprunginnovationsprojekt geht neue Wege in der Alzheimer-Therapie

11. Februar 2021

Alzheimer´s Research: Important Milestone for PRI-002
Alzheimer´s Research: Important Milestone for PRI-002

4. Februar 2021

Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board
Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board

9. Dezember 2020

New CEO of Priavoid
New CEO of Priavoid

2. September 2020

Priavoid Headquarters at LSC Düsseldorf
Priavoid Headquarters at LSC Düsseldorf

6. März 2020

Seed Investment
Seed Investment

6. Mai 2019

Prof. Willbold´s interview with PharmaVentures
Prof. Willbold´s interview with PharmaVentures

23. Januar 2018

Clinical trial with PRI-002
Clinical trial with PRI-002

31. Mai 2017

  • Home
  • Investors and Media
  • Legal Notice
  • Privacy Policy
  • Contact us
Copyright © 2021 Priavoid GmbH